Liquidia Technologies has started early clinical testing of its first vaccine developed using nanotechnology.
The Durham company, which has raised $25 million in financing this year, is testing a seasonal flu vaccine aimed at adults over 65.
Liquidia is also developing experimental cancer treatments and other products based on the nanotechnology research of founder Joseph DeSimone, a chemist at N.C. State and UNC Chapel Hill.
The flu vaccine will require years of clinical testing before it can win marketing approval from U.S. regulators. The vaccine is designed to have tiny particles deliver the medicine more safely and effectively.